VALNEVA to Present at the 17th World Vaccine Congress in Washington D.C.

Valneva to Present at the 17^th World Vaccine Congress in Washington D.C.

Lyon (France), April 10, 2017 - Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine company, announced today that it will be holding two presentations on Lyme disease and mosquito-transmitted diseases on April 11, 2017 at the 17^th World Vaccine Congress in Washington DC. Over 600 vaccine specialists will converge to the event.

Valneva's CEO, Thomas Lingelbach, will focus on the development of a novel vaccine for protection against Lyme disease, the most common infection following an insect bite in the US. The Centers for Disease Control (CDC) estimates that 300,000 Americans^[1] contract Lyme disease each year, calling it "a major US public health problem". The presentation will include an update on Valneva's development strategy for its Lyme disease vaccine VLA 15 which entered Phase I clinical trial in the US and Europe at the beginning of the year. Pre-clinical data showed that VLA 15 has the potential for protection against the majority of Borrelia species pathogenic for humans^[2].

Valneva will also present on vaccine development against emerging mosquito-transmitted diseases, including its vaccine candidates against diseases caused by Zika-, Chikungunya- and Yellow fever- virus infections, building on the key competencies it has developed from its successful bench to market development of its Japanese Encephalitis vaccine.

Thomas Lingelbach, President and CEO and Franck Grimaud, Deputy CEO of Valneva commented, "This congress is a great opportunity for Valneva to present its clinical portfolio to leading vaccine industry experts and to underline the strong medical needs which exit for the vaccines that the Company is currently developing. We are also looking forward to meeting our current partners and discussing new potential collaborations."

Valneva, a gold sponsor of the event, will have a display in the exhibit area adjacent to the conference facilities, at booth number 27.

About Valneva SE

Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva's portfolio includes two commercial vaccines for travelers: IXIARO ^(R)/JESPECT ^(R) indicated for the prevention of Japanese encephalitis and DUKORAL ^(R) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme disease. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66 ^(R) vaccine production cell line, IC31 ^(R) adjuvant).

Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at www.valneva.com.

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, theability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

^[1] Latest data from the CDC (PR on Aug 19, 2013);

^[2] http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113294

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/082951d2-3037-4580-898e-c42ffeb0a6c5